U pstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Stage II chronic obstructive pulmonary disease, also known as moderate stage COPD. By stage II, your symptoms are usually no longer something you can just shrug off. They start to affect your ...

As of late Friday morning the air quality levels around Montezuma County have reached moderate levels, according to the U.S.

The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, COPD exacerbation history groups were “mediocre” in estimating moderate and severe exacerbation risk at 1 and 4 ...

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

In the moderate COPD group, 561 patients received ensifentrine and 307 received placebo, and these numbers were slightly lower in the severe COPD group, with 414 patients receiving ensifentrine ...

COPD cannot be reversed. However, quitting smoking, managing any allergies, and following an exercise program may help slow its progression.

PULMONARY hypertension is a serious and relatively frequent complication of the ostiumsecundum type of defect of the atrial septum.1 2 3 4 It increases the symptoms ...

Phase 2 trial launched for verekitug in COPD, expanding treatment indications for severe respiratory conditions. Top data expected in 2026.